Members of the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) group along with experienced ...

Wedbush initiated coverage on Zenas BioPharma, Inc. (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company focused ...

Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

Baseline factors linked to SLE flares during pregnancy included thrombocytopenia and a history of LN, while antimalarial therapy demonstrated protective effects.

As previously reported, Wedbush initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating and $35 price target The firm notes its ...

In December 2024, the National Comprehensive Cancer Network® (NCCN) added AUCATZYL (obecabtagene autoleucel) to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of ...

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

Syncona Shs GBP ( ($GB:SYNC) ) has provided an announcement. Autolus Therapeutics, a portfolio company of Syncona Ltd, has announced its 2024 ...

Zenas BioPharma (ZBIO) stock rises as Wedbush issues a bullish recommendation based on the company's lead asset obexelimab. Read more here.

U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and ...

A new study finds that ChatGPT4 provides answers to lupus patient questions as effectively as rheumatologists, excelling in ...